A Phase IIa/IIb, randomised, double blind, placebo-controlled, parallel-group dose-finding study to examine the efficacy and safety of BI 1839100 administered orally over a 12-week treatment period in patients with idiopathic pulmonary fibrosis or progressive pulmonary fibrosis with clinically meaningful cough.

Primary objective: To demonstrate a meaningful reduction from baseline in 24-h cough frequency (defined as the cough
counts (CC) measured over 24 h and averaged per hour, i.e. CC/h) in the highest dose group of BI 1839100 compared
with placebo after 4 weeks of treatment. Geometric means and mean ratios will be the summary measures of treatment
effect for the change from baseline in each group and differences between treatment groups